Skip to main content
Premium Trial:

Request an Annual Quote

Securities Firm Ups ABI s Stock, Share Price Target on Strong Fiscal Q3 Earnings

NEW YORK, April 28 (GenomeWeb News) - Piper Jaffray yesterday increased Applied Biosystems' 12-month share price target yesterday and increased the company's rating to 'Outperform.'


The securities firm now expects ABI's shares to reach $33 within 12 months. It had expected it to reach $27. The stock closed up to $28.50 yesterday.


As GenomeWeb News reported yesterday, ABI said that fiscal third-quarter sales increased 8 percent as R&D spending declined 6 percent and profits surged 121 percent.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.